https://apnews.com/Globe%20Newswire/5f340ac37ee044e098fd1a843cb46b08 The treatment with leronlimab is targeted as a therapy for patients who experience respiratory complications as a result of contracting SARS-CoV-2 causing the Coronavirus Disease 2019 (COVID-19). Leronlimab is believed to provide therapeutic benefit by enhancing the immune response while mitigating the “cytokine storm” that leads to morbidity and mortality in these patients. The laboratory evaluation of the first four patients treated with leronlimab revealed that the immune profile in these patients approached normal levels and the levels of cytokines involved in the cytokine storm (including IL-6 and TNF alpha) were much improved. The results of the three additional patients are expected this week.
Leronlimab (PRO 140) has been used in a number of patients with COVID-19 (coronavirus) as part of two clinical trials applications that have been fast tracked by the FDA. The first trial being applied for is to study the leronlimab in patients with mild to moderate COVID-19 respiratory symptoms. The second trial that is being applied for will study leronlimab in patients with severe COVID-19 respiratory symptoms.
可以阻止细胞因子风暴，这一点和托珠单抗类似，同时还可以增强免疫系统反应。 https://apnews.com/Globe%20Newswire/5f340ac37ee044e098fd1a843cb46b08 The treatment with leronlimab is targeted as a therapy for patients who experience respiratory complications as a result of contracting SARS-CoV-2 causing the Coronavirus Disease 2019 (COVID-19). Leronlimab is believed to provide therapeutic benefit byenhancing the immune response while mitigating the “cytokine storm”that leads to morbidity and mortality in these patients. The laboratory evaluation of the first four patients treated with leronlimab revealed that the immune profile in these patients approached normal levels and the levels of cytokines involved in the cytokine storm (including IL-6 and TNF alpha) were much improved. The results of the three additional patients are expected this week. 现在正在做两个trial，包括轻症和危重症： https://www.drugs.com/medical-answers/leronlimab-pro-140-treat-covid-19-coronavirus-3535182/ Leronlimab (PRO 140) has been used in a number of patients with COVID-19 (coronavirus) as part of two clinical trials applications that have been fast tracked by the FDA. The first trial being applied for is to study the leronlimab in patients with mild to moderate COVID-19 respiratory symptoms. The second trial that is being applied for will study leronlimab in patients with severe COVID-19 respiratory symptoms. genechn 发表于 3/31/2020 2:17:00 AM
https://apnews.com/Globe%20Newswire/5f340ac37ee044e098fd1a843cb46b08
The treatment with leronlimab is targeted as a therapy for patients who experience respiratory complications as a result of contracting SARS-CoV-2 causing the Coronavirus Disease 2019 (COVID-19). Leronlimab is believed to provide therapeutic benefit by enhancing the immune response while mitigating the “cytokine storm” that leads to morbidity and mortality in these patients. The laboratory evaluation of the first four patients treated with leronlimab revealed that the immune profile in these patients approached normal levels and the levels of cytokines involved in the cytokine storm (including IL-6 and TNF alpha) were much improved. The results of the three additional patients are expected this week.
现在正在做两个trial，包括轻症和危重症：
https://www.drugs.com/medical-answers/leronlimab-pro-140-treat-covid-19-coronavirus-3535182/
Leronlimab (PRO 140) has been used in a number of patients with COVID-19 (coronavirus) as part of two clinical trials applications that have been fast tracked by the FDA.
The first trial being applied for is to study the leronlimab in patients with mild to moderate COVID-19 respiratory symptoms.
The second trial that is being applied for will study leronlimab in patients with severe COVID-19 respiratory symptoms.
不知道其它抗艾滋的药是怎么起作用的，Leronlimab是一种靶向CCR5的人源化IgG4单抗，用途很广泛。如
https://med.sina.com/article_detail_100_2_65739.html
如果指克立芝的话，完全不一样
不是吧？我也是小白，但是听说抗艾滋的药是抗病毒复制，艾滋病毒并不会引起免疫风暴，会摧毁免疫系统。